利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.012 秒)

    Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
    2.
    发明公开
    Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them 审中-公开
    萘啶衍生物，它们的制备方法，它们的用途以及含有它们的摘要的药物组合物

    公开(公告)号：EP1065207A1

    公开(公告)日：2001-01-03

    申请号：EP99112636.8

    申请日：1999-07-02

    申请人： Aventis Pharma Deutschland GmbH ,  Genentech, Inc.

    发明人： Peyman, Anuschirwan Dr. ,  Scheunemann, Karl-Heinz Dr. ,  Gourvest, Jean-Francois Dr. ,  Ruxer, Jean-Marie Dr. ,  Gadek, Thomas R. Dr.

    IPC分类号： C07D473/34 ,  A61K31/52

    CPC分类号： C07D473/34

    摘要： The present invention relates to compounds of the formula I,
    in which B, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

    摘要翻译： 本发明涉及式I化合物，其中B，G，Z，X，Y，R，S和T具有权利要求书所指出的含义，它们的生理学可耐受的盐及其前药。 式I化合物是有价值的药理学活性化合物。 它们是玻连蛋白受体拮抗剂和细胞粘着的抑制剂，并适合于基于哪个在细胞 - 细胞或细胞 - 基质相互作用的过程或可预防，减轻或玻连蛋白受体和它们的配体之间的相互作用的疾病的治疗和预防 通过影响寻求互动治愈。 例如，它们可以应用于抑制由破骨细胞骨再吸收，因此用于治疗和预防骨质疏松症，或用于抑制血管平滑肌肉细胞的不期望的血管或增殖。 本发明进一步更涉及式I，它们的使用，特别是作为药物中的活性成分，以及包含它们的药物组合物的化合物的制备方法。

    Substituted purine derivatives as inhibitors of cell adhesion
    3.
    发明公开
    Substituted purine derivatives as inhibitors of cell adhesion 审中-公开
    替代物Purin Derivate als Inhibitoren der Zell-Adhäsion

    公开(公告)号：EP1065208A1

    公开(公告)日：2001-01-03

    申请号：EP99112637.6

    申请日：1999-07-02

    申请人： Aventis Pharma Deutschland GmbH ,  Genentech, Inc.

    发明人： Knolle, Jochen Dr. ,  Peyman, Anuschirwan Dr. ,  Gourvest, Jean-Francois Dr. ,  Ruxer, Jean-Marie Dr. ,  Gadek, Thomas R. Dr.

    IPC分类号： C07D473/34 ,  A61K31/52

    CPC分类号： C07D473/34

    摘要： The present invention relates to compounds of the formula I,
    in which B, D, E, G, X, Y, Z, R 1 , R 2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

    摘要翻译： 本发明涉及式I化合物，其中B，D，E，G，X，Y，Z，R 1，R 2和s具有权利要求书中所示的含义， 生理上可耐受的盐及其前药。 式I的化合物是有价值的药理活性化合物。 它们是玻连蛋白受体拮抗剂和细胞粘附抑制剂，并且适用于治疗和预防基于玻连蛋白受体及其配体在细胞 - 细胞或细胞 - 基质相互作用过程中的相互作用的疾病，或可被预防，缓解或 通过影响这种相互作用来治愈。 例如，它们可以用于抑制破骨细胞的骨吸收，从而用于治疗和预防骨质疏松症，或用于抑制血管平滑肌肉细胞的细胞的不期望的血管生成或增殖。 本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。